0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > Protein > PD-1 > PD1-H522a

Human PD-1 / PDCD1 Protein, His Tag, low endotoxin (MALS verified)

Order Now

  • Synonym
    PDCD1,PD1,CD279,SLEB2
  • Source
    Human PD-1 Protein, His Tag(PD1-H522a) is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Gln 167 (Accession # NP_005009.2).
    Predicted N-terminus: Leu 25
  • Molecular Characterization
    PD-1 Structure

    This protein carries a polyhistidine tag at the C-terminus, and has a calculated MW of 16.8 kDa. The N-terminus Sequence Analysis is Leu 25. The reducing (R) protein migrates as 31-44 kDa in SDS-PAGE due to glycosylation.

  • Endotoxin
    Less than 0.01 EU per μg by the LAL method.
  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
PD-1 SDS-PAGE

Human PD-1 Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-MALS
PD-1 MALS images

The purity of Human PD-1 Protein, His Tag (Cat. No. PD1-H522a) is more than 85% and the molecular weight of this protein is around 25-40 kDa verified by SEC-MALS.

Bioactivity-ELISA
 PD-1 ELISA

Immobilized Human PD-1 Protein, His Tag (Cat. No. PD1-H522a) at 2 μg/mL (100 μL/well) can bind Human PD-L2, Mouse IgG1 Fc Tag (Cat. No. PD2-H52A5) with a linear range of 10-156 ng/mL (Routinely tested).

Bioactivity-BLI
 PD-1 BLI

Loaded Human PD-1 Protein, His Tag (Cat. No. PD1-H522a) on HIS1K Biosensor, can bind Human PD-L1, Fc Tag (Cat. No. PD1-H5258) with an affinity constant of 23.3 nM as determined in BLI assay (ForteBio Octet Red96e) (QC tested).

 PD-1 BLI

Loaded Human PD-1 Protein, His Tag (Cat. No. PD1-H522a) on HIS1K Biosensor, can bind Human PD-L2 Protein, Fc Tag (Cat. No. PD2-H5251) with an affinity constant of 15.7 nM as determined in BLI assay (ForteBio Octet Red96e) (QC tested).

 PD-1 BLI

Loaded Human PD-L1, Fc Tag (Cat. No. PD1-H5258) on Protein A Biosensor, can bind Human Human PD-1 Protein, His Tag (Cat. No. PD1-H522a) with an affinity constant of 4.8 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

 PD-1 BLI

Loaded Human PD-L2 Protein, Fc Tag (Cat. No. PD2-H5251) on Protein A Biosensor, can bind Human Human PD-1 Protein, His Tag (Cat. No. PD1-H522a) with an affinity constant of 0.9 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

  • Background
    Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer.
  • Clinical and Translational Updates

Comments (0)


ETA des produits en stock: 2 jours ouvrables

Price(EUR) : €460.00

Price(EUR) : €2670.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:16 Details
  • Number of Drugs in Clinical Trials:150 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop

Laisser un message